Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVO-2 pneumococcal PCV20 booster response study in adults aged 78-84 years
NL-OMON58981Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Prevnar 20 in pneumococcal disease, sponsored by National Institute for Public Health and the Environment. Primary endpoint: Serum PCV20-specific antibody response at 1 month. Started Aug 2025; status: active, not recruiting.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NL-OMON58981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58981.